查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球宫颈癌诊断市场 - 2023-2030年
市场调查报告书
商品编码
1289782

全球宫颈癌诊断市场 - 2023-2030年

Global Cervical Cancer Diagnostics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球宫颈癌诊断市场的规模在2022年达到81亿美元，预计到2030年将见证有利可图的增长，达到130亿美元。在2023-2030年的预测期内，宫颈癌诊断市场预计将呈现6.3%的复合增长率。

作为宫颈癌诊断的一部分，各种测试和技术被用于诊断和监测宫颈癌和癌前疾病。额外的程序，如淋巴结活检、膀胱镜、直肠镜或PET-CT（正电子发射断层扫描-计算机断层扫描）等成像测试，被用来确定宫颈癌的阶段。

市场动态

活跃的主要参与者和宫颈癌诊断产品的推出，在预测期内推动了全球宫颈癌诊断市场的增长。

对于女性来说，宫颈癌是一种典型的恶性肿瘤。近年来，随着发病率和死亡率的增加，出现了明显的年轻化趋势。唯一有明确病因并可通过早期检测治愈的癌症是宫颈癌。例如，由新视野健康公司开发的CerviClear测试，是世界上第一个基于尿液的HPV检测和宫颈癌筛查测试。

它完成了无创的家庭尿液自我取样，是唯一完全覆盖所有14种高危HPV病毒的解决方案。由于该产品已经获得了CE标志，因此有资格在香港和大湾区推出。

消费者对宫颈癌的认识不断提高，在预测期内推动了全球宫颈癌诊断市场的增长。

宫颈癌是最容易预防的癌症之一，它每年在印度妇女中造成近77000人死亡。例如，2023年4月，致力于促进癌症认识、预防和早期检测的非营利组织 - 癌症意识预防和早期检测信托基金（CAPED）与罗氏诊断印度公司签署了一份谅解备忘录（MoU）。

与CAPED的关系是罗氏诊断印度公司最近的一项倡议，旨在消除与该疾病相关的社会污名，提高对宫颈癌检查的认识。罗氏诊断印度公司致力于在国际上降低宫颈癌的发病率。

诊断测试的高成本在预测期内阻碍了全球宫颈癌诊断市场的增长。

宫颈癌诊断测试的价格会因几个变量而不同，包括特定的测试、地点、医疗机构的环境和现有的医疗系统。巴氏试验的费用从20美元到100美元不等，这取决于地方和医疗专业人士。

此外，HPV DNA测试的费用从50美元到200美元或更多，取决于实验室和所采用的精确测试技术。阴道镜检查的费用可能在200美元到800美元之间，取决于地区、医疗专业人员和检查期间进行的任何额外程序。

COVID-19影响分析

COVID-19大流行病对宫颈癌诊断市场产生了重大影响。这场大流行给医疗系统带来了压力，限制了宫颈癌诊断服务的提供。

诊断测试的延迟，如巴氏涂片测试、HPV测试、阴道镜检查和活检，被认为是由于缺乏资源、医疗机构负担过重以及工作人员被转用于COVID-19应对行动。

截至2023年，COVID-19的情况正在恢复，所有病人都可以进入医疗机构，推动了宫颈癌诊断市场的发展。

俄罗斯-乌克兰冲突分析

俄乌战争对宫颈癌诊断市场的影响是复杂和多方面的。人们可能因战斗而流离失所，交通可能中断，并可能设立军事检查站。这些障碍可能会限制人们进入医疗设施，使人们难以获得及时的宫颈癌诊断和其他医疗服务。

此外，在冲突时期，医疗资源和努力被重新定向，以集中于创伤护理、应急反应和紧急医疗需求。这导致公共卫生措施减少，如宣传活动和宫颈癌筛查计划，这将降低筛查率并推迟诊断。

目录

第一章：方法和范围

  • 研究方法
  • 报告的研究目标和范围

第二章：定义和概述

第三章：执行摘要

  • 按测试类型抽查
  • 按年龄组分类的摘要
  • 按销售渠道分类
  • 按地区分类

第四章：动态变化

  • 影响因素
    • 驱动因素
      • 宫颈癌发病率的增加
    • 限制因素
      • 诊断测试的高成本
    • 机会
      • 技术进步
    • 影响分析

第五章：行业分析

  • 波特五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第六章：COVID-19分析

  • 对COVID-19的分析
    • COVID-19之前的情况
    • COVID-19期间的情况
    • COVID-19之后的情况
  • 在COVID-19期间的定价动态
  • 需求-供应谱系
  • 大流行期间与市场有关的政府倡议
  • 制造商的战略倡议
  • 结语

第7章 ：俄罗斯-乌克兰战争分析

第八章：人工智能分析

第九章：按测试类型

  • 巴氏涂片测试
  • HPV DNA测试
  • 结肠镜检查
  • EEC测试
  • 其他测试

第十章：按年龄组划分

  • 21岁以下
  • 21-29
  • 30-65
  • 65岁及以上

第十一章：按分销渠道分类

  • 医院药房
  • 医院药房
  • 电子商务

第十二章：按地区划分

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东和非洲

第13章 ：竞争格局

  • 竞争格局
  • 产品标杆
  • 公司份额分析
  • 主要发展和战略

第十四章：公司简介

  • QIAGEN
    • 公司概述
    • 产品组合和描述
    • 财务概况
    • 主要发展情况
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Guided Therapeutics
  • Olympus
  • Cardinal Health
  • Siemens Healthcare
  • Hologic, Inc.
  • Quest Diagnostics
  • Abbott Laboratories

第十五章 ：附录

简介目录
Product Code: CD1901

Market Overview

The Global Cervical Cancer Diagnostics Market size reached USD 8.1 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 13 billion by 2030. The cervical cancer diagnostics market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.

A variety of tests and techniques are employed in the diagnosis and monitoring of cervical cancer and precancerous diseases as part of cervical cancer diagnostics. Additional procedures, such as lymph node biopsy, cystoscopy, proctoscopy or imaging tests like PET-CT (positron emission tomography-computed tomography), are carried out to ascertain the stage of cervical cancer.

Market Dynamics

Active Major Players and Cervical Cancer Diagnostic Product Launches are Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

For women, cervical cancer is a typically malignant tumor. In recent years, there has been an apparent trend of rejuvenation along with an increase in morbidity and mortality. The only cancer that has a clear etiology and may be cured with early detection is cervical cancer. For instance, the CerviClear test, developed by New Horizon Health, is the world's first urine-based HPV detection and cervical cancer screening test.

It accomplishes non-invasive home-based urine self-sampling and is the only solution that completely covers all 14 high-risk HPV viruses. The product is eligible to be introduced in Hong Kong and the Greater Bay Area because it already possesses a CE Mark.

The Growing Awareness Among Consumers About Cervical Cancer is Boosting the Global Cervical Cancer Diagnostics Market Growth During the Forecast Period.

Cervical cancer is one of the most preventable cancers, it accounts for nearly 77,000 deaths among Indian women each year. For instance, in April 2023, the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection, and Roche Diagnostics India signed a Memorandum of Understanding (MoU).

The relationship with CAPED is one recent initiative by Roche Diagnostics India to remove the societal stigma associated with the disease and raise awareness about cervical cancer screening. Roche Diagnostics India is dedicated to reducing the incidence of cervical cancer internationally.

The High Cost of Diagnostic Tests is Hampering the Global Cervical Cancer Diagnostics Market Growth in the Forecast Period.

The price of cervical cancer diagnostic tests can vary depending on several variables, including the particular test, location, the environment for the medical facility and the healthcare system in existence. Pap tests can cost from $20 and $100, depending place and healthcare professionals.

In addition, HPV DNA tests cost from $50 to $200 or more, depending on the lab and the precise testing technique employed. A colposcopy operation might cost between $200 and $800, depending on the area, the healthcare professional and any extra procedures carried out during the examination.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the cervical cancer diagnostics market. The pandemic has put pressure on healthcare systems, which has restricted the availability of cervical cancer diagnostic services.

Delays in diagnostic testing, such as Pap smear tests, HPV tests, colposcopies and biopsies, have been attributed to a lack of resources, overburdened healthcare institutions and the redirection of workers to COVID-19 response operations.

As of 2023, the COVID-19 situation is recovering and all patients can access healthcare facilities driving the cervical cancer diagnostics market.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the cervical cancer diagnostics market is complex and multifaceted. People may be displaced by the combat, transportation may be disrupted, and military checkpoints may be set up. These obstacles may limit access to medical facilities, making it difficult for people to get prompt cervical cancer diagnoses and other healthcare services.

In addition, healthcare resources and efforts were redirected during times of conflict to focus on trauma care, emergency response and urgent medical needs. This results in fewer public health measures, such as awareness campaigns and cervical cancer screening programs, which would lower screening rates and postpone diagnosis.

Segment Analysis

The global cervical cancer diagnostics market is segmented based on test type, age group, distribution channel, end-user and region.

The HPV DNA Test Segment is Expected to Hold the 2nd Dominant Position in the Market Over the Forecast Period.

The HPV DNA test segment accounted for the 2nd highest market stake accounting for approximately 27.6% of the cervical cancer diagnostics market in 2022. An HPV test examines a sample of cells to see if they have a high-risk form of the virus. If such an infection persists for a long time, it may alter cervical cells and result in cervical cancer.

For instance, in September 2022, to test for high-risk HPV types in individuals, Mylab Discovery Solutions introduced the "PathoDetect HPV Detection Test," a real-time PCR-based screening tool. 'PathoDetect HPV Detection Test' is a regulatory authority-approved test that finds and distinguishes the presence of high-risk HPV strains, such as strains 16 and 18, which are responsible for the majority of cervical cancers.

Geographical Analysis

Increasing Collaborations and Partnerships Among the Key Players, Increasing Prevalence of Cervical Cancer and Advancement in Cervical Cancer Diagnostics Dominate the North American Region.

North America is expected to dominate the cervical cancer diagnostics market, accounting for around 38.9% of the market share. As per the article published in the International Journal of Gynecological Cancer in 2022, when examining the trends over time, it was discovered that the prevalence of cervical cancer in its remote stages increased annually at a rate of 1.3% (p 0.001). Cervical adenocarcinoma has the highest growth, with an average yearly percent change of 2.9% (p 0.001).

White women in the South aged 40-44 have the biggest increase in distant cervical cancer at a rate of 4.5% annually (p0.001), according to an intersecting analysis of race, location and age.

Competitive Landscape

The major global players in the market include: QIAGEN Becton, Dickinson and Company F. Hoffmann-La Roche Ltd. Guided Therapeutics Olympus Cardinal Health Siemens Healthcare Hologic, Inc. Quest Diagnostics Abbott Laboratories among others.

Why Purchase the Report?

  • To visualize the global cervical cancer diagnostics market segmentation based on the test type, age group, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cervical cancer diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Cervical Cancer Diagnostics Market Report Would Provide Approximately 61 Tables, 60 Figures and 195 pages.

Target Audience 2023

  • Manufacturers / Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Incidence of Cervical Cancer
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of diagnostic tests
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advances
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Test Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 9.1.2. Market Attractiveness Index, By Test Type
  • 9.2. Pap Smear Test*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. HPV DNA Test
  • 9.4. Coloscopy
  • 9.5. EEC Test
  • 9.6. Others

10. By Age Group

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 10.1.2. Market Attractiveness Index, By Age Group
  • 10.2. Below 21*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. 21-29
  • 10.4. 30-65
  • 10.5. 65 and Above

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Hospital Pharmacies
  • 11.4. E-Commerce

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. The U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. The U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. QIAGEN*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Becton, Dickinson and Company
  • 14.3. F. Hoffmann-La Roche Ltd.
  • 14.4. Guided Therapeutics
  • 14.5. Olympus
  • 14.6. Cardinal Health
  • 14.7. Siemens Healthcare
  • 14.8. Hologic, Inc.
  • 14.9. Quest Diagnostics
  • 14.10. Abbott Laboratories

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us